What you'll learn

  • Appraise the benefits and risks of SGLT2 inhibitors and GLP-1 receptor agonists in people with type 2 diabetes mellitus, heart failure and chronic kidney disease

  • Formulate a comprehensive pharmacotherapeutic plan to reduce cardiovascular and kidney risk in people with type 2 diabetes mellitus, heart failure and chronic kidney disease

  • Describe models for the co-management of people with increased cardiovascular and kidney risk by physicians and pharmacists

Course description

Many recent initiatives have designed care models that incorporate pharmacists into the initiation, titration and monitoring of drug therapy. In this presentation, we will describe current approaches to pharmacist and physician collaborative practices and their effect on care optimization using a cardiovascular-renal-metabolic collaborative clinic as an example. This information will assist pharmacists with designing and implementing their own care models to improve update of novel therapies.

This is an accredited, livestreamed course offered by Harvard Medical School as part of the Contemporary Pharmacotherapy: Collaborative Clinical Explorations series. This course is targeted to pharmacists, pharmacy residents, physicians, physician assistants, clinicians, medical residents, nurses and nurse practitioners.

Select the Take Course button to view additional information on the course registration page.

Contact ceprograms@hms.harvard.edu with questions.

You may also like

Online

Learn foundational concepts in genetics and gain new insight into the rapidly evolving field of genomics.

Price
$800
Registration Deadline
In-Person

This course will outline the National Comprehensive Cancer Network’s (NCCN) accepted guidelines, and highlight updates to staging, treatment and indications for neoadjuvant and adjuvant therapy.

Price
$50 - $150
Registration Deadline
Starts Apr 11